Latest Cynapsus Therapeutic (CYNAF) Headlines Cynapsus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Cynapsus Therapeutic (CYNAF) Headlines

Cynapsus Therapeutics Announces DTC Approval
Marketwire - Thu Feb 27, 8:24AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC") to facilitate electronic settlement of transfers of its common shares in the United States.

Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
Marketwire - Thu Feb 13, 7:02AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson's disease, today announced the appointment of Nan Hutchinson to the Board of Directors.

LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
Marketwire - Fri Feb 07, 8:15AM CST
LifeSci Advisors, LLC announcement for Cynapsus Therapeutics, Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF)

Cynapsus Therapeutics Announces Exercise of Warrants
Marketwire - Thu Jan 23, 3:01PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. Following the exercise of these warrants, Cynapsus has 39,009,335 commons shares, 21,426,439 warrants and 2,691,316 options to purchase common shares outstanding.

Cynapsus Announces Resignation of Chief Scientific Officer
Marketwire - Wed Jan 22, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities.

Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
Marketwire - Mon Jan 13, 5:01AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of "OFF" episodes in Parkinson's disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines.

SeeThruEquity, LLC Initiates Coverage on Cynapsus Therapeutics Inc.
Marketwire - Tue Nov 26, 8:03AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that SeeThruEquity, LLC, an independent investment research and corporate access firm, has initiated equity research coverage on the Company. The research report is available for viewing and downloading at www.seethruequity.com.

Cynapsus Therapeutics Reports Third Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Nov 21, 3:43PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease, today announced its results for the nine months ended September 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.

Cynapsus Therapeutics Reports Second Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Aug 22, 3:18PM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the six months ended June 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.

Cynapsus Therapeutics Is First to Develop Convenient Delivery of Apomorphine for Parkinson's Patients Experiencing "OFF" Episodes, Says Zacks Analyst via Interview With the Life Sciences Report
Marketwire - Mon Aug 05, 8:37AM CDT
Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Cynapsus Therapeutics Inc. (OTCQX: CYNAF) (TSX VENTURE: CTH) is a small Canadian company developing a sublingual formulation of a drug called apomorphine, which is a rescue medication for Parkinson's disease patients who experience something called 'off time,' a rigid or frozen state that occurs when their levodopa + carbidopa medication has worn off. This typically happens in the morning, because the Parkinson's patient takes his or her last dose of medication before bed, and it has worn off by the time they awaken. Apomorphine is a rapid rescue medication for that "off time" state. Cynapsus' sublingual film formulation of apomorphine is put under the tongue and dissolves in a very short period of time. Patients with dyskinesia can take it themselves. It just makes sense.

Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Begins Trading on the OTCQX Marketplace in the United States
Marketwire - Thu Jul 18, 6:07AM CDT
July 18, 2013

Cynapsus Therapeutics Inc. (CYNA) Stock Research Links

CYNA Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Main Street Merger Faces Scrutiny: What It Means for Shareholders

Updated Category News Views 0

Under the Radar, but Not for Long Ah, mergers—those grand gestures in corporate America that promise growth, synergy, and shareholder value. But not every deal is a head-turner; some fly under the radar until someone grabs the magnifying glass. And that's exactly what's happening with Main Street Financial Services Corp.'s (OTC: MSWV) proposed merger with First...

Continue Reading
Investigation of Maplebear Sale to DoorDash Sparks Debate

Updated Category News Views 121

Shareholders Fret Over Maplebear's Proposed Transaction It ain't every day a deal's got shareholders fidgeting more than a cat in a dog park, but here we are. Maplebear Inc. (NASDAQ: CART) finds itself under the magnifying glass as the seasoned crew over at Monteverde & Associates PC sound the alarm bells. The firm, sitting cozy in the Empire State Building, is on the...

Continue Reading
Greenberg Traurig's 93 Attorneys Shine on Super Lawyers List

Updated Category News Views 65

A Legal Powerhouse Expands Its Reputation Just when you think you've got the legal market pegged, something like this pops up: Greenberg Traurig's 93 attorneys make it onto the coveted 2026 New York Metro Super Lawyers lists. We're talking about 59 making the 'Super Lawyers' list and 34 slipping into the 'Rising Stars' category. They even had Vice Chairman Robert J....

Continue Reading
Nanoscope Therapeutics Aims for Eye-Catching Advances

Updated Category News Views 69

Gearing Up for a Boston Showcase Nanoscope's High-Stakes Boston Rendezvous In a move set to grab some serious eyeballs, Nanoscope Therapeutics is geared up to strut their stuff at Advanced Therapies USA 2026 in Boston. Scheduled for November 4–5 at the Hynes Convention Center, the event isn't just another pitstop—it's a billboard for what these guys have cooking. With...

Continue Reading
Sabey Data Centers Tests HVO to Cut Emissions

Updated Category News Views 68

Exploring New Horizons in Data Center Energy A curious tale is unfolding down in Austin, Texas, folks—one where data centers meet renewable energy in a bid to clean up their act. Sabey Data Centers is giving good old-fashioned diesel the boot in favor of hydrotreated vegetable oil (HVO) for backup power. We're not talking about minor tweaks here; this is about testing...

Continue Reading
Food Emulsifiers Surge: Market to Hit $5.60B by 2031

Updated Category News Views 72

Forecasting Growth in Food Emulsifiers Picture this: the food emulsifiers market is steaming ahead, anticipating a thunderous boom from $4.43 billion in 2026 to a whopping $5.60 billion by 2031. According to recent estimates, that's a steady clip at a CAGR of 4.8%. If you're thinking that's just more industry chatter, let's peel back the layers and see what makes this...

Continue Reading
Membrane Chromatography Market Surges with Biologics Boom

Updated Category News Views 84

Another Chapter in Chromatography: What's New? It's like this: membrane chromatography is getting its day in the sun, and it's about time we dive into why it's happening. Projected to scale up from $0.37 billion in 2026 to a neat $0.63 billion by 2031, we’re talking a solid 11.3% compound annual growth rate. It's a tale of tech advancements and rising demand for...

Continue Reading
transcosmos Boosts Supply Chain with AI-Powered Tools

Updated Category News Views 62

No-Nonsense Supply Chain Evolution at transcosmos Take a hard look at the chaos flying around the supply chain arena these days. It's like every time you turn your head, there's a new twist landing folks into deeper complexity. Look, if you thought supply chain management was a snooze of a topic, think again because transcosmos just dialed up the intensity with its...

Continue Reading
Co-op Giants Earn $309B: Key Players Spotlighted

Updated Category News Views 167

Co-ops Punch Above Their Weight Forget the tired stereotypes about co-ops as small-time players. The NCB Co-op 100® Report lands like a punch with a staggering revelation: $309 billion in revenue for 2025. That's no small potatoes, and it shows these cooperatives, sprinkled across agriculture, finance, and beyond, are no shy creatures—they're major contenders in...

Continue Reading
European Doctors Explore Chinese Aesthetic Innovations

Updated Category News Views 39

Pioneering Exchange in Regenerative Aesthetics Ever seen European doctors flocking to China to learn about beauty techniques? That's the scene as aphranel®, the brainchild of MOYOM Biotech, ushers in a week-long clinical exchange under 'The Norns' Weave.' The whole deal aims to unravel how Chinese practices could shape Europe's aesthetic landscape. Yep, it's all about...

Continue Reading

Top 5 Most Recently Viewed Articles

Simon Property Group Achieves New Heights with Stock Surge

Updated Category News Views 60

Simon Property Group Hits a New 52-Week High Simon Property Group Inc. (NYSE: SPG) has achieved an impressive milestone with its stock reaching a stunning 52-week high of $169.21. This achievement is remarkable for a company renowned for managing top-tier shopping, dining, and entertainment venues. The stock's rise reflects a remarkable 50.71% increase over the past year,...

Continue Reading
ChemoMetec Reports Impressive Growth in Q1 Revenue and EBITDA

Updated Category News Views 161

ChemoMetec Sees Substantial Revenue Growth in Q1 2025/26 In the recent trading update for the first quarter of 2025/26, ChemoMetec demonstrated remarkable performance with an 8% increase in revenue, reaching DKK 124.6 million compared to DKK 115.6 million during the same period last year. This includes an impressive 11% growth when adjusting for constant exchange rates,...

Continue Reading
Niutech's Innovative Pyrolysis Tech and Its Global Impact

Updated Category News Views 178

Niutech's Commitment to Sustainable Solutions At the forefront of tackling plastic pollution, Niutech has emerged as a leader in pyrolysis technology, showcasing its capabilities at global conferences. The company's continuous plastic pyrolysis technology is revolutionizing how we manage waste, transforming low-value, mixed, and polluted plastics into valuable chemical...

Continue Reading
Simon Property Group Sets Q3 Earnings Call Date and Details

Updated Category News Views 43

Simon Property Group Announces Q3 Earnings Call Information Simon Property Group, a respected real estate investment trust known for its ownership of premier shopping, dining, entertainment, and mixed-use destinations, has unveiled the schedule for its third quarter earnings release and subsequent conference call. This announcement highlights the company’s ongoing...

Continue Reading
NCC Group plc: Insights from Recent Trading Activities

Updated Category News Views 132

Understanding Recent Trading Activities of NCC Group plc The world of finance often spins with activity and interactions that may not always be visible to the average investor. Today, we focus on NCC Group plc and its recent trading activities that shed light on its market positioning and future outlook. Key Information on Trading To begin, it’s essential to acknowledge...

Continue Reading